Vyvanse Shortage: What Providers and Prescribers Need to Know in 2026

If you prescribe Vyvanse (lisdexamfetamine dimesylate) for ADHD or binge eating disorder, you've likely fielded a growing number of patient calls about availability. This briefing covers the current supply landscape, what changed, and what you can do to help your patients access their medication in 2026.

Complete Timeline: How We Got Here

2007: Vyvanse (brand, Takeda) receives FDA approval for ADHD treatment.

2015: FDA expands approval to include binge eating disorder (BED) in adults.

October 2022: The FDA officially adds amphetamine mixed salts to its drug shortage database, signaling broader stimulant supply disruptions.

2023: Generic lisdexamfetamine enters the market as Vyvanse's patent exclusivity expires. Eleven generic manufacturers receive FDA approval—including Teva, Alvogen, and others—but production ramp-up takes time.

Late 2024: The DEA approves a 24% increase in amphetamine production quotas, aiming to close the gap between supply and demand.

2025–2026: Brand Vyvanse (Takeda) is not in shortage. However, generic lisdexamfetamine remains in shortage from some suppliers, creating localized availability gaps that continue to frustrate patients and providers alike.

What the Shortage Resolution Means for Your Prescribing Practice

The distinction between brand and generic availability is critical for clinical decision-making in 2026:

• Brand Vyvanse is consistently available at most pharmacies, but at a significantly higher cost ($400–$558/month without insurance).
• Generic lisdexamfetamine remains subject to intermittent supply constraints from certain manufacturers, meaning patients may face delays or need to check multiple pharmacies.
• Prior authorization complexity: Many insurers require step therapy or prior authorization for brand Vyvanse when generics are formulary-preferred. When a patient can't find the generic, navigating PA for brand coverage adds administrative burden.
• Indication-specific coverage: Coverage for BED indications may differ from ADHD coverage on some plans, adding another layer of complexity.

The Real-World Availability Picture

Understanding the supply chain helps explain why your patients still struggle, even after quota increases:

• Manufacturer → wholesaler → pharmacy: Even when manufacturers produce adequate supply, wholesaler allocation limits can restrict how much any single pharmacy receives in a given period.
• Dose-specific variation: Certain dosage strengths (particularly 30mg, 50mg, and 70mg) may be more constrained than others due to demand patterns.
• Regional disparities: Urban areas with high ADHD prescribing volumes may experience more pronounced shortages than rural areas—and vice versa for pharmacies with limited wholesaler relationships.

Cost and Access: The Numbers Your Patients Are Seeing

Cost is a top reason patients abandon stimulant therapy. Here's what your patients face in 2026:

• Brand Vyvanse: $400–$558/month without insurance
• Generic lisdexamfetamine: $68–$440/month, depending on pharmacy and discount card. With a GoodRx coupon, prices can be as low as $68/month.
• Takeda savings card: Eligible commercially insured patients may pay as little as $30/month through Takeda's copay assistance program.
• Patient assistance programs: Takeda's Help at Hand program provides free Vyvanse to qualifying uninsured or underinsured patients.
• Medicare/Medicaid: Coverage varies by plan. Part D plans typically cover generic lisdexamfetamine, but brand Vyvanse may require prior authorization or be non-formulary.

Tools and Resources for Your Practice

• Medfinder provider portal: Search for pharmacies with Vyvanse or generic lisdexamfetamine in stock on behalf of your patients. Medfinder's dedicated support team contacts pharmacies directly to verify real-time availability.
• FDA Drug Shortage Database: Monitor official shortage status and manufacturer updates.
• Takeda savings and support: Direct patients to Vyvanse.com/coupon for copay card enrollment, or to Takeda's patient assistance program for uninsured patients.

Looking Ahead

Several factors could improve the Vyvanse availability landscape in 2026 and beyond:

• Manufacturing expansion: With the DEA's 24% quota increase and 11 approved generic manufacturers, production capacity continues to scale.
• New formulations: Watch for potential new delivery mechanisms or dosage forms that could expand options for patients.
• Payer policy shifts: As generic supply stabilizes, insurers may adjust formulary placement and prior authorization requirements.

Final Thoughts

Providers are on the front lines of the Vyvanse availability challenge. Here's what to keep in mind:

1. Brand Vyvanse is available, but cost is a significant barrier for many patients.
2. Generic lisdexamfetamine supply is improving but remains inconsistent from some suppliers.
3. Tools like the Medfinder provider portal can save your staff time by verifying pharmacy stock on your patients' behalf.
4. Proactively discussing cost and availability with patients improves adherence and outcomes.

For more on helping your patients navigate Vyvanse access, see our provider's guide to finding Vyvanse in stock and our guide to Vyvanse savings programs for providers. You can also share our patient-facing shortage update with your patients directly.